Merck is restructuring its pharmaceutical business into Oncology and Specialty/Infectious Diseases divisions ahead of Keytruda's patent expiration. The company announced positive late-stage clinical results for Keytruda combinations in ovarian and bladder cancer, showing significant improvements in survival and reduced risk of disease progression. New data also showed promising results for Welireg and Lenvima combinations in renal cell carcinoma. Concurrently, the company announced staff cuts at an HPV vaccine factory.